Better Choice Company Inc. (BTTR) Q3 2024 Earnings Call Transcript Summary
Better Choice Company Inc. (BTTR) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Better Choice Company Inc. (BTTR) Q3 2024 Earnings Call Transcript:
以下是Better Choice Company Inc.(BTTR)2024年第3季度業績會議記錄摘要:
Financial Performance:
財務表現:
Better Choice Company reported a quarter-over-quarter sales growth of 33% to $11.4 million.
Achieved a gross margin of 40%, marking the third consecutive quarter of improvement.
Reported the first profitable quarter in years with adjusted EBITDA just north of $200,000.
Generated net income of $1.5 million for Q3 and earnings per share of $0.74.
Better Choice Company報告季度銷售額同比增長33%,達到1140萬美元。
實現40%的毛利率,標誌着連續第三個季度的改善。
報告了多年來首個盈利季度,調整後的EBITDA略高於20萬美元。
第三季度淨利潤爲150萬美元,每股收益爲0.74美元。
Business Progress:
業務進展:
Significant operational discipline and improved S&OP process led to a 48% year-over-year reduction in inventory and an average fill rate of 97%.
Experienced substantial year-over-year growth in international markets, particularly in the Asia-Pacific region.
Increased focus on digital channels resulted in double-digit growth in new-to-brand and repeat consumers.
Announced the acquisition of SRx Health, expected to complete in early Q1 2025, which will enhance operational efficiencies and contribute to sustainable growth.
顯著的運營紀律和改善的S&OP流程導致庫存同比減少48%,平均填充率達到97%。
在國際市場,尤其是亞太地域板塊,經驗了可觀的年度增長。
加大對數字渠道的關注,導致新用戶和復購消費者實現兩位數增長。
宣佈收購SRx Health,預計將在2025年初完成,這將提高運營效率並促進可持續增長。
Opportunities:
機會:
The demographic shift in Asia, particularly in China, represents a significant opportunity for expansion in the pet food market.
The acquisition of SRx Health positions Better Choice to capitalize on increased operational efficiencies and access expanded markets in specialty healthcare.
亞洲的人口結構變化,特別是在中國,爲寵物食品市場的擴張提供了重要機會。
收購SRx Health將使Better Choice能夠利用提高的運營效率並進入特殊醫療保健領域的擴展市場。
Risks:
風險:
No explicit risks mentioned.
未提及明顯風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。